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Background: Cytokine expression is known to play a role in progression of heart failure (HF). Paracrine signaling is thought to be one 
mechanism of action in cell-based therapies for HF. Human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CMs) and 
mesenchymal stem cells (hMSCs) intervention may play a role in changing the microenvironment milieu to allow for endogenous cellular 
repair through paracrine signaling.
methods: Sprague-Dawley rats underwent LAD ligation, resulting in HF after 3 wks. Echocardiograms were performed and rats were 
randomized to cell-based therapies with a fibroblast patch (patch only), hiPSC-CM patch, MSCs via tail vein (IV) or intracardiac injections 
(IC) to the left ventricle (LV). Repeat echocardiograms and end-point hemodynamics were obtained prior to RNA isolation and real-
time polymerase chain reaction (PCR) was performed for analysis of gene expression of connexin 43 (Cx43), angiopoeitin 1 (Ang-1), 
angiopoietin 2 (Ang-2), insulin like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF) were evaluated.
results: The hiPSC-CM patch increased (p<0.05) Cx43, Ang1, Ang 2, IGF-1 and VEGF expression as compared to HF or sham animals. 
In addition, hMSCs as sole therapy increased interleukin 1 receptor antagonist (IL-1rn) expression, but did not significantly increase 
expression of angiogenesis makers. Furthermore, hMSCs as adjuvant therapy with the patch showed significant (p<0.05) improvements in 
VEGF and IGF-1 expression.
conclusion:  Upregulation of angiogenic cytokines, anti-inflammatory and cardioprotective cytokines may help in slowing progression of 
HF. The use of a hiPSC-CM patch showed significant (p<0.05) improvements in echocardiography and hemodynamics. Both hiPSC-CM 
patch and hMSCs altered signaling, perhaps leading to improvement of HF at the cellular level. A hiPSC-CM patch and hMSCs adjuvant 
therapy may be able to play a significant role in the setting of HF as cellular therapeutics.
